Lincoln Pharmaceuticals Intrinsic Value
LINCOLN • Healthcare
Current Stock Price
₹584.00
Primary Intrinsic Value
₹878.24
Market Cap
₹1168 Cr
+5.6%
Upside
Median Value
₹616.76
Value Range
₹255 - ₹878
Assessment
Trading Near Calculated Value
Safety Margin
5.3%
LINCOLN Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹878.24 | ₹702.59 - ₹1053.89 | +50.4% | EPS: ₹39.92, Sector P/E: 22x |
| Book Value Method | asset | ₹672.00 | ₹604.80 - ₹739.20 | +15.1% | Book Value/Share: ₹336.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹684.00 | ₹615.60 - ₹752.40 | +17.1% | Revenue/Share: ₹342.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹660.00 | ₹594.00 - ₹726.00 | +13.0% | EBITDA: ₹132.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹480.22 | ₹384.18 - ₹576.26 | -17.8% | CF Growth: 7.7%, Discount: 15% |
| PEG Ratio Method | growth | ₹255.49 | ₹229.94 - ₹281.04 | -56.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹616.76 | ₹555.08 - ₹678.44 | +5.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹480.00 | ₹432.00 - ₹528.00 | -17.8% | ROE: 11.9%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹549.36 | ₹494.42 - ₹604.30 | -5.9% | EPS: ₹39.92, BVPS: ₹336.00 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
LINCOLN Intrinsic Value Analysis
What is the intrinsic value of LINCOLN?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Lincoln Pharmaceuticals (LINCOLN) is ₹616.76 (median value). With the current market price of ₹584.00, this represents a +5.6% variance from our estimated fair value.
The valuation range spans from ₹255.49 to ₹878.24, indicating ₹255.49 - ₹878.24.
Is LINCOLN undervalued or overvalued?
Based on our multi-method analysis, Lincoln Pharmaceuticals (LINCOLN) appears to be trading near calculated value by approximately 5.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 26.32 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 11.9% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 16.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.86x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Lincoln Pharmaceuticals
Additional stock information and data for LINCOLN
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹93 Cr | ₹54 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹63 Cr | ₹35 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹39 Cr | ₹21 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹76 Cr | ₹37 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹69 Cr | ₹37 Cr | Positive Free Cash Flow | 8/10 |